185 related articles for article (PubMed ID: 24752275)
1. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.
Montgomery AB; Rhomberg PR; Abuan T; Walters KA; Flamm RK
Antimicrob Agents Chemother; 2014 Jul; 58(7):3714-9. PubMed ID: 24752275
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.
Perdigão-Neto LV; Oliveira MS; Rizek CF; Carrilho CM; Costa SF; Levin AS
Antimicrob Agents Chemother; 2014; 58(3):1763-7. PubMed ID: 24323469
[TBL] [Abstract][Full Text] [Related]
4. Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.
Montgomery AB; Rhomberg PR; Abuan T; Walters KA; Flamm RK
Antimicrob Agents Chemother; 2014 Jul; 58(7):3708-13. PubMed ID: 24752276
[TBL] [Abstract][Full Text] [Related]
5. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
6. Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.
Rajenderan S; Balaji V; Anandan S; Sahni RD; Tansarli GS; Falagas ME
PLoS One; 2014; 9(7):e103253. PubMed ID: 25068396
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Karlowsky JA; Hoban DJ; Hackel MA; Lob SH; Sahm DF
J Med Microbiol; 2017 Jan; 66(1):61-69. PubMed ID: 28051952
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.
Flamm RK; Rhomberg PR; Lindley JM; Sweeney K; Ellis-Grosse EJ; Shortridge D
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858207
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].
Adaleti R; Nakipoğlu Y; Arıcı N; Kansak N; Çalık Ş; Şenbayrak S; Balık R; Aksaray S
Mikrobiyol Bul; 2023 Jul; 57(3):365-377. PubMed ID: 37462301
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
Demir T; Buyukguclu T
Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
[TBL] [Abstract][Full Text] [Related]
14. The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria.
Williams PCM; Waichungo J; Gordon NC; Sharland M; Murunga S; Kamau A; Berkley JA
J Med Microbiol; 2019 May; 68(5):711-719. PubMed ID: 30994430
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
16. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.
Kastoris AC; Rafailidis PI; Vouloumanou EK; Gkegkes ID; Falagas ME
Eur J Clin Pharmacol; 2010 Apr; 66(4):359-68. PubMed ID: 20186407
[TBL] [Abstract][Full Text] [Related]
17. Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries.
Kakaraskoska Boceska B; Vilken T; Xavier BB; Kostyanev T; Lin Q; Lammens C; Ellis S; O'Brien S; da Costa RMA; Cook A; Russell N; Bielicki J; Riddell A; Stohr W; Walker AS; Berezin EN; Roilides E; De Luca M; Romani L; Ballot D; Dramowski A; Wadula J; Lochindarat S; Boonkasidecha S; Namiiro F; Ngoc HTB; Tran MD; Cressey TR; Preedisripipat K; Berkley JA; Musyimi R; Zarras C; Nana T; Whitelaw A; da Silva CB; Jaglal P; Ssengooba W; Saha SK; Islam MS; Mussi-Pinhata MM; Carvalheiro CG; Piddock LJV; Heath PT; Malhotra-Kumar S; Sharland M; Glupczynski Y; Goossens H
Nat Commun; 2024 May; 15(1):3947. PubMed ID: 38729951
[TBL] [Abstract][Full Text] [Related]
18. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.
Falagas ME; Kanellopoulou MD; Karageorgopoulos DE; Dimopoulos G; Rafailidis PI; Skarmoutsou ND; Papafrangas EA
Eur J Clin Microbiol Infect Dis; 2008 Jun; 27(6):439-43. PubMed ID: 18214558
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and antibiotic resistance profiles of Gram negative bacilli associated with urinary tract infections (UTIs) in Karachi, Pakistan.
Rasool MS; Siddiqui F; Ajaz M; Rasool SA
Pak J Pharm Sci; 2019 Nov; 32(6):2617-2623. PubMed ID: 31969294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
